Last updated: May 27, 2026
Deferiprone Suppliers: Who Manufactures and Supplies the API and Finished Dosage Globally?
Deferiprone supply is split between (1) active pharmaceutical ingredient (API) manufacturers that produce the drug substance and (2) finished-dose suppliers that package tablets/capsules under national marketing authorizations. For business planning, the most decision-relevant view is the API sourcing base (including DMF holders) and the finished-goods players that sell deferiprone products in each market.
Who supplies deferiprone as the API (drug substance) globally?
Featured snippet answer: Deferiprone API is supplied by a limited set of specialized small-molecule manufacturers, and supply often tracks DMF-based qualification rather than broad, commodity-style sourcing. Finished-dose brands typically source deferiprone API from one or more qualified API producers and then manufacture/pack under local regulatory frameworks.
API supplier categories that matter for procurement
- DMF/ASMF holders and commercial API makers
These are the highest-leverage suppliers for qualification because dossiers support regulatory submissions.
- Contract manufacturers that produce API under license or toll manufacturing arrangements
These suppliers may not market API under their own brand but provide manufacturing capacity.
- Finished-dose manufacturers that internally control API sourcing
Some companies produce API and drug product in one supply chain for continuity.
API grades and specs procurement teams should align
- Polymorph and particle size controls (where specified)
- Residual solvents and impurities profile
- Assay and water content
- Stability and shelf-life evidence for tablets/capsules
- DMF cross-reference to match the company’s regulatory file strategy
Which companies sell deferiprone tablets or capsules (finished dosage) by country?
Featured snippet answer: Finished-dose supply is dominated by brand and generic manufacturers that hold marketing authorizations in each jurisdiction. Their supply chain typically depends on qualified API sources plus local packaging/manufacturing partners.
Product forms seen in the market
- Film-coated tablets (common in many markets)
- Scored tablets (where dose flexibility is required)
- Oral formulations (selected markets; dependent on local approvals)
- Strength variations (often aligning with local label dosing schemes)
Procurement view: finished-dose vs API
- If your goal is clinical or pre-launch manufacturing, API sourcing and DMF strategy dominate.
- If your goal is market distribution, finished-dose supply depends on import licensing, batch release capability, and tender/contracting practices in the destination country.
What is the Orange Book status of deferiprone and how does that affect sourcing?
Featured snippet answer: Deferiprone is not generally managed like newer U.S. Hatch-Wax exclusivity molecules; the practical effect on sourcing is through the availability of approved generics/authorized products and the regulatory standing of drug product approvals, not through a single Orange Book-style exclusivity regime.
Why U.S. listing status matters for supply
- It affects which drug products are eligible for substitution and procurement.
- It affects which manufacturers have current FDA-reviewed labeling and cGMP track records, which in turn influences qualification timelines.
Which FDA pathways and regulatory dossiers drive deferiprone supplier eligibility?
Featured snippet answer: Supplier eligibility is driven by whether the applicant’s product relies on FDA-referenced DMFs for the API, AND whether the drug product is supported by bioequivalence and CMC evidence under the applicable pathway.
Regulatory dossier elements procurement should map
- API DMF or ASMF reference
- Drug product application (and manufacturing site approvals)
- Stability protocols
- Comparability and change-control history (for any supplier transitions)
How many deferiprone API suppliers exist, and where are the dominant manufacturing regions?
Featured snippet answer: Deferiprone API supply is concentrated in a small number of specialized global manufacturers, with manufacturing capacity often centered in Asia and Europe. Exact counts and ranking vary with year-to-year qualification and capacity moves.
Sourcing concentration risk
Procurement risk for deferiprone typically comes from:
- limited API qualification dependencies (few cross-referenced DMFs)
- batch timing and release bottlenecks at qualified sites
- change-control lead times during API resourcing
What patent or exclusivity barriers affect deferiprone supplier entry?
Featured snippet answer: Deferiprone is an established therapy; supplier barriers are less about fundamental molecule exclusivity and more about regulatory qualification, CMC data access, and ongoing product quality history.
Where barriers show up in practice
- reliance on referenced impurity profiles and historical batch quality
- restrictions tied to specific polymorph/grade used in reference products
- stability and shelf-life acceptance for drug product changeovers
- manufacturing site authorization status (FDA/EMA and local regulators)
How do generic or alternate suppliers qualify deferiprone for commercial supply?
Featured snippet answer: Qualification generally follows demonstrated bioequivalence for drug product applicants plus API dossier support via DMF cross-reference and CMC acceptance.
Common qualification workstreams
- vendor onboarding with technical package review
- DMF cross-reference verification (or full CMC support where applicable)
- risk review for impurities, residuals, and specification alignment
- engineering batches and comparative stability plans
- regulatory transfer readiness for manufacturing site changes
What formulation and packaging requirements influence deferiprone supplier selection?
Featured snippet answer: Tablets and other solid oral forms drive selection toward suppliers with robust compressibility/flow characteristics, validated coating processes, and packaging systems that protect against moisture and stability drift.
Packaging and handling
- blister vs bottle (market dependent)
- desiccant use (if specified)
- humidity-controlled storage assumptions during distribution
Quality system signals procurement screens
- deviations history and CAPA responsiveness
- batch-to-batch variability (assay, impurities)
- consistency of dissolution profiles tied to grade selection
What supply-chain disruptions are most likely for deferiprone?
Featured snippet answer: Supply interruptions most often stem from API capacity constraints, batch release delays at a small number of qualified sites, and changeovers that extend qualification timelines.
Disruption precursors that procurement can monitor
- short lead times and high MOQ on API
- recent DMF changes or site transfers
- rising impurity excursions across batches
- delayed stability pull data affecting retest windows
Key Takeaways
- Deferiprone supply is driven by a limited, qualification-based API and finished-dose ecosystem rather than broad commodity availability.
- Supplier selection hinges on DMF/CMC compatibility, drug product manufacturing authorization, and validated stability/packaging controls.
- In commercial planning, the key risk is concentration at qualified API and drug product sites, which affects continuity of supply and qualification speed.
FAQs
- How do I evaluate deferiprone API suppliers for regulatory readiness (DMF/ASMF alignment)?
- What difference does blister vs bottle packaging make for deferiprone tablet stability?
- How long does a deferiprone API vendor change typically take to qualify in finished drug product?
- What CMC tests most often fail during deferiprone generic transition (impurities, dissolution, residual solvents)?
- Which procurement metrics best predict deferiprone batch release reliability from API vendors?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. FDA. Drug Master Files (DMF). https://www.fda.gov/drugs/drug-master-files-dmf
